USPTO Reinstates Double Patenting Rejections In Ex Parte Baurin: What Life Sciences Innovators Need to Know

On August 6, 2026, the USPTO Appeals Review Panel (ARP) reinstated nonstatutory double patenting (NSDP) rejections against Sanofi’s application for antibody-like binding proteins. This precedential decision has significant implications for life sciences companies developing and improving upon innovative therapies….
By: Foley Hoag LLP